Safe use of Olygose GOS supported by new peer-reviewed publications
18 Sep 2017 --- French natural ingredients manufacturer Olygose has announced that new peer-reviewed publications support the safe use of plant-based galacto-oligosaccharides (GOS) from Olygose from infancy to older age.
“We have reached an important milestone with the publication of this safety data set,” says François Delbaere, CEO of Olygose. “The excellent safety profile observed will definitely support the expansion of our presence on the market and greatly facilitate the regulatory challenges that any company that is involved in specialized nutrition markets, such as infant nutrition, has to face.”
Olygose Friday announced the release of two new publications confirming the safety of plant-based galacto-oligosaccharides evaluated during a 90-day sub-chronic toxicity test in rats (OECD guideline 408) and a repeated dose study in piglets. The two manuscripts have been published in Toxicology Research and Application during summer and are available here.
Separate trials produce safety-affirming results
The 90-day sub-chronic toxicity trial, performed with CiToxLAB (France), aimed at providing information on health hazards likely to arise from exposure to plant-based GOS via oral administration and indicated that the no observed adverse effect level (NOAEL) for Olygose plant-based GOS is greater than 2000 mg per kg per day.
The neonatal piglet trial, performed with US toxicology testing and research laboratory Experimur, demonstrated that plant-based GOS incorporated at a level of 8 g/L in a formula (the maximum dose of prebiotic substance added to infant formulas) was well tolerated and did not cause harmful effects. The neonatal piglet is the best translational model available to date to evaluate the safety of new substances aimed at being incorporated in infant formulas.
Olygose says its plant-based GOS are produced in France “thanks to a proprietary technology resulting in very pure ingredients suitable for a number of applications in the field of foods, beverages and supplements.” They are currently marketed in Europe and the US under different brand names, namely AlphaGOS for prebiotic and symbiotic formulations, CravingZ’Gone for satiety and weight management and P-GOS for infant nutrition applications.
Olygose points out in its press release that its proprietary syrups and powders offer clinically-supported benefits in fields such as microbiome implantation and efficiency, satiety and metabolic syndrome. It says their taste and processing characteristics provide for an easy incorporation in infant formulas and baby foods, as well as in dietary supplements.
